GSA Capital Partners’s Sophiris Bio, Inc. SPHS Stock Holding History

GSA Capital Partners’s Portfolio SPHS Stock Details SPHS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-38,400	Closed	-$84K	–	2071
2017 Q2	$84K	Buy	+38,400	New	+$94.1K	0.01%	1604

Other funds holding SPHS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CAN

Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

GSA Capital Partners's SPHS Position: Q3 2017 in Review

GSA Capital Partners sold out of Sophiris Bio, Inc. (SPHS) in Q3 2017, closing a stake of 38,400 shares — an estimated $84K sold.

GSA Capital Partners first reported a position in SPHS in Q2 2017 and held it in 1 quarter. The position peaked at $84K in Q2 2017. 25 funds tracked by Wall St. Rank hold SPHS as of Q3 2017.

GSA Capital Partners reported no remaining Sophiris Bio, Inc. position as of Q3 2017 after selling out during the quarter.
GSA Capital Partners sold 38,400 Sophiris Bio, Inc. shares in Q3 2017, an estimated $84K.
GSA Capital Partners first reported a position in Sophiris Bio, Inc. in Q2 2017 and held it in 1 quarter.
GSA Capital Partners's Sophiris Bio, Inc. position peaked at $84K in Q2 2017.
25 funds tracked by Wall St. Rank held Sophiris Bio, Inc. as of Q3 2017.

Based on GSA Capital Partners's 13F filing for Q3 2017, filed 20 Nov 2017.